The antibodies cyclic citrullinated peptides (anti-CCP) positivity could be a promising marker in brucellosis patients presented with peripheric arthritis

REFERENCES

• Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol. 1994;33(8):735–9.
   Google Scholar
• Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, et al. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152:456–64.
   PubMed Web of Science ®Google Scholar
• Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006;6:91–9.
   PubMed Web of Science ®Google Scholar
• Hashemi SY, Keramat F, Ranjbar M, Mamani M, Farzam A, Jamal-Omidi S. Osteoarticular complications of brucellosis in Hamedan, an endemic area in the west of Iran. Int J. Infect Dis. 2007;11:496–500.
   Google Scholar
• Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifesta-tions and complications in 1028 cases of brucellosis: a retro-spective evaluation and review of the literature. Int J. Infect Dis. 2009;10:469–78.
   Google Scholar
• Pourbagher A, Pourbagher MA, Savas L, et al. Epidemiologic, clinical and imaging findings in brucellosis patients with osteo-articular involvement. MR Am J Roentgenol. 2006;187:873–80.
   PubMed Web of Science ®Google Scholar
• Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone; 2005. p. 2669–72.
   Google Scholar
• Damian-Abrego GN, Cabiedes J, Cabral AR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus. 2008;17:300–4.
   Google Scholar
• Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrulli-nated peptide and anti-keratin antibodies in patients with primary Sjiigren's syndrome. Ann Rheum Dis. 2005;64:114–7.
   Google Scholar
• Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol. 2008;27: 77–83.
   Google Scholar
• Lima Isabella. Antibodies against cyclic citrullinated peptides in infectious diseases—a systematic review. Clin Rheumatol. 2010;29:1345–51.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Alarcon GS, Bocanegra TS, Gotuzzo E, Espinoza LR. The arthritis of brucellosis: a perspective one hundred years after Bruce's discovery. J Rheumatol. 1987;14:1083–4.
   PubMed Web of Science ®Google Scholar
• Elkayam 0, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006;65:1110–2.
   Google Scholar
• Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML. Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheu-matoid factor and anti-cyclic citrullinated peptide antibody. J Autoimmun. 2007;28(1):55–8.
   Google Scholar
• Lim MK, Shim TS, Sheen DH, Na DJ, Min SS, Shim SC. An-ticyclic citrulline peptide antibody in non-tuberculous mycobac-teria sera: a negative association. Clin Rheumatol. 2010;29(3): 335–6.
   PubMedGoogle Scholar
• Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheuma-toid arthritis in patients with chronic HBV infection. J Rheuma-tol. 2009;36(4):712–6.
   PubMedGoogle Scholar
• Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155–63.
   PubMed Web of Science ®Google Scholar
• Guedes-Barbosa LS, Mangueira C, Scheinberg M. Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association. Clin Rheumatol. 2008;27: 515–6.
   Google Scholar
• Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58(6):1576–81.
   PubMedGoogle Scholar
• Ceri M, Unverdi S, Altay M, ereten K, Oztiirk M, Gonen N, Duranay M. Anti-cyclic citrullinated peptides positivity rate in patients with familial Mediterranean fever. Clin Exp Rheumatol. 2010;28:58–61.
   Google Scholar
• Koga T, Migita K, Miyashita T, Maeda Y, Nakamura M, Abiru S, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol. 2008;26(1):121–4.
   PubMedGoogle Scholar
• Makrygiannakis D, Af KE, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L, et al. Citrullination is an inflammation dependent process. Ann Rheum Dis. 2006;65(9):1219–22.
   PubMed Web of Science ®Google Scholar